An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis

• Status: Recruiting
• Trial end date: 2023-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Phase 2 study of RPT193 in adults with atopic dermatitis

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: RAPT Therapeutics, Inc.

Criteria

Inclusion Criteria:

• Clinically confirmed diagnosis of active atopic dermatitis (AD), according to the revised Hanifin and Rajka criteria

• 12-month history of AD and had no significant flares in AD for at least 4 weeks before screening

• inadequate response to a ≥1 month treatment with topical medications

• Atopic dermatitis covering ≥10% of the body surface area

• EASI score ≥16

• Validated Investigator Global Assessment (VIGA) ≥3

• Use of emollient(s) at least 2x daily for 1 week prior to baseline

• Negative coronavirus disease (COVID)-19 results at screening

Exclusion Criteria:

• Uncontrolled moderate-to-severe asthma

• Uncontrolled diabetes

• Stage III or IV cardiac failure

• Severe renal condition

• Major surgery within 8 weeks of screening

• Immunodeficiency and/or receipt of immunosuppressive drugs within 4 weeks of baseline

• Use of systemic Janus kinase (JAK) inhibitor within 8 weeks of baseline

• Received live or live-attenuated vaccine within 4 weeks of baseline

• Prior receipt of RPT193